Cogent Biosciences, Inc.
US ˙ NasdaqGS ˙ US19240Q2012

SecurityCOGT / Cogent Biosciences, Inc.
InstitutionFmr Llc
Latest Disclosed Ownership16,569,256 shares
Ownership 15.00%
Fmr Llc ownership in COGT / Cogent Biosciences, Inc.

2025-02-12 - Fmr Llc has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 16,569,256 shares of Cogent Biosciences, Inc. (US:COGT). This represents 15.0 percent ownership of the company. In their previous filing dated 2024-11-07 , Fmr Llc had reported owning 13,208,972 shares, indicating an increase of 25.44 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2025-02-12 2025-02-12 13G/A 13,208,972 16,569,256 25.44 15.00 24.30
2024-11-07 2024-11-07 13G/A 5,302,854 8,319,411 56.89 7.60 23.45
2024-11-07 2024-11-07 13G/A 5,302,854 13,208,972 149.09 12.07 96.00
2024-02-09 2024-02-09 13G 946,343 5,302,854 460.35 6.16 95.15
2019-02-13 2019-02-13 13G/A 2,412,590 946,343 -60.77 3.15 -61.26
2018-04-05 2018-04-05 13G 2,412,590 8.14

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F COGENT BIOSCIENCES COM 19240Q201 23,122,748 35,781 0.15 889,995 8.53 0.0093
2026-02-17 2025-12-31 13F COGENT BIOSCIENCES COM 19240Q201 23,086,967 678,704 3.03 820,049 154.85 0.0418
2025-11-13 2025-09-30 13F COGENT BIOSCIENCES COM 19240Q201 22,408,263 5,329,795 31.21 321,783 162.42 0.0167
2025-08-14 2025-06-30 13F COGENT BIOSCIENCES COM 19240Q201 17,078,468 1,139 0.01 122,623 19.87 0.0069
2025-05-12 2025-03-31 13F COGENT BIOSCIENCES COM 19240Q201 17,077,329 508,073 3.07 102,293 -20.85 0.0065
2025-02-13 2024-12-31 13F COGENT BIOSCIENCES COM 19240Q201 16,569,256 8,249,845 99.16 129,240 43.84 0.0077
2024-11-13 2024-09-30 13F COGENT BIOSCIENCES COM 19240Q201 8,319,411 625,743 8.13 89,850 38.53 0.0055
2024-08-13 2024-06-30 13F COGENT BIOSCIENCES COM 19240Q201 7,693,668 729,060 10.47 64,858 38.58 0.0042
2024-05-13 2024-03-31 13F COGENT BIOSCIENCES COM 19240Q201 6,964,608 1,661,754 31.34 46,802 50.10 0.0031
2024-02-13 2023-12-31 13F COGENT BIOSCIENCES COM 19240Q201 5,302,854 733,073 16.04 31,181 -30.02 0.0024
2023-11-13 2023-09-30 13F COGENT BIOSCIENCES COM 19240Q201 4,569,781 4,248,521 1,322.46 44,555 1,071.58 0.0039
2023-08-11 2023-06-30 13F COGENT BIOSCIENCES COM 19240Q201 321,260 275,620 603.90 3,804 672.97 0.0003
2023-08-11 2023-03-31 13F/A-1 COGENT BIOSCIENCES COM 19240Q201 45,640 -1,095,851 -96.00 492 -96.27 0.0000
2023-05-11 2023-03-31 13F COGENT BIOSCIENCES COM 19240Q201 45,640 -1,095,851 492 0.0000
2023-02-13 2022-12-31 13F COGENT BIOSCIENCES COM 19240Q201 1,141,491 -157,552 -12.13 13,196 -31.92 0.0013
2022-11-10 2022-09-30 13F COGENT BIOSCIENCES COM 19240Q201 1,299,043 44,693 3.56 19,382 71.31 0.0020
2022-08-12 2022-06-30 13F COGENT BIOSCIENCES COM 19240Q201 1,254,350 842,796 204.78 11,314 266.98 0.0011
2022-05-13 2022-03-31 13F COGENT BIOSCIENCES COM 19240Q201 411,554 22,421 5.76 3,083 -7.67 0.0002
2022-02-14 2021-12-31 13F COGENT BIOSCIENCES COM 19240Q201 389,133 389,046 447,179.31 3,339 333,800.00 0.0002
2022-02-14 2021-09-30 13F/A-1 COGENT BIOSCIENCES COM 19240Q201 87 87 1 0.0000
2021-11-15 2021-09-30 13F COGENT BIOSCIENCES COM 19240Q201 87 87 1 0.0000
2021-08-13 2021-06-30 13F UNUM THERAPEUTICS COM 19240Q201 0 -3 -100.00 0 0.0000
2021-05-14 2021-03-31 13F UNUM THERAPEUTICS COM 19240Q201 3 -9,026 -99.97 0 -100.00
2021-02-08 2020-12-31 13F COGENT BIOSCIENCES COM 19240Q201 9,029 -391,356 -97.74 101 -89.22 0.0000
2020-11-13 2020-09-30 13F UNUM THERAPEUTICS COM 903214104 400,385 -500 -0.12 937 409.24 0.0001
2020-08-24 2020-06-30 13F/A-1 UNUM THERAPEUTICS COM 903214104 400,885 0 0.00 184 11.52 0.0000
2020-08-13 2020-06-30 13F UNUM THERAPEUTICS COM 903214104 400,885 0 184 4.5203
2020-05-14 2020-03-31 13F UNUM THERAPEUTICS COM 903214104 400,885 0 0.00 165 -42.71 0.0000
2020-02-07 2019-12-31 13F UNUM THERAPEUTICS COM 903214104 400,885 0 0.00 288 -50.17 0.0000
2019-11-13 2019-09-30 13F UNUM THERAPEUTICS COM 903214104 400,885 500 0.12 578 -44.90 0.0001
2019-08-13 2019-06-30 13F UNUM THERAPEUTICS COM 903214104 400,385 -1,609 -0.40 1,049 -40.57 0.0001
2019-05-13 2019-03-31 13F UNUM THERAPEUTICS COM 903214104 401,994 -544,349 -57.52 1,765 -57.61 0.0002
2019-02-13 2018-12-31 13F UNUM THERAPEUTICS COM 903214104 946,343 -1,466,247 -60.77 4,164 -83.24 0.0006
2018-11-09 2018-09-30 13F UNUM THERAPEUTICS COM 903214104 2,412,590 0 0.00 24,850 -28.22 0.0028
2018-08-10 2018-06-30 13F UNUM THERAPEUTICS COM 903214104 2,412,590 0 0.00 34,621 19.58 0.0041
2018-05-14 2018-03-31 13F UNUM THERAPEUTICS COM 903214104 2,412,590 2,412,590 28,951 0.0034
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.